Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/144727
Title: Systemic therapies for mucopolysaccharidosis: Ocular changes following haematopoietic stem cell transplantation or enzyme replacement therapy - a review
Authors: Summers, C. Gail
Fahnehjelm, Kristina T.
Pitz, Susanne
Guffon, Nathalie
Koseoglu, Selim T.
Harmatz, Paul
Scarpa, Maurizio 
Keywords: Enzyme replacement therapy;Eye manifestation;Hematopoietic stem cell transplantation;Mucopolysaccharidosis;Therapeutic
Keywords Plus: BONE-MARROW-TRANSPLANTATION;LYSOSOMAL STORAGE DISORDERS;HUNTER-SYNDROME;CORD-BLOOD;VI;MANAGEMENT;CHILDREN;DISEASE;GUIDELINES;EXPERIENCE
Issue Date: 1-Aug-2010
Publisher: WILEY
Journal: Clinical and Experimental Ophthalmology 
Abstract: 
Abstract: The management of mucopolysaccharidosis (MPS) is focused on the multi-organ, sometimes life-threatening, clinical manifestations that occur over time. In the past, the limited, symptom-based treatment options led physicians to adopt a palliative approach towards individual disease-associated complications. The availability of systemic treatments such as haematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) has created a better prognosis for MPS patients, particularly when initiated early in life. As part of an integrated management approach, these therapies could be valuable in managing the ocular features that are present in many children with MPS. HSCT has been shown to stabilize or improve corneal clouding and optic nerve oedema for the majority of patients. Retinal degeneration, in contrast, seems not to be permanently arrested. ERT was more recently introduced and has therefore been less well examined than HSCT; with respect to ocular problems in MPS, the majority of reports indicate stabilization of corneal clouding or visual acuity. However, controversy remains about its effect on other ocular pathologies. Despite the lack of consistent ophthalmic improvement for all patients, both treatment modalities deserve consideration, because even reducing MPS-related eye disease progression is worthwhile. © 2010 The Authors. Journal compilation © 2010 Royal Australian and New Zealand College of Ophthalmologists.
URI: http://hdl.handle.net/20.500.12857/144727
ISSN: 14426404
DOI: 10.1111/j.1442-9071.2010.02366.x
Appears in Collections:Articles

Show full item record

SCOPUSTM   
Citations

17
checked on Sep 3, 2020

WEB OF SCIENCETM
Citations

23
checked on Nov 28, 2021

Page view(s) 10

1
checked on Nov 29, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.